JP2005504517A - ＣＤ４４ｖ６特異的抗体 - Google Patents

ＣＤ４４ｖ６特異的抗体 Download PDF

Info

Publication number
JP2005504517A
JP2005504517A JP2002592353A JP2002592353A JP2005504517A JP 2005504517 A JP2005504517 A JP 2005504517A JP 2002592353 A JP2002592353 A JP 2002592353A JP 2002592353 A JP2002592353 A JP 2002592353A JP 2005504517 A JP2005504517 A JP 2005504517A
Authority
JP
Japan
Prior art keywords
antibody
seq
acid sequence
nucleic acid
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002592353A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005504517A5 (https=
Inventor
ギュンター アドルフ
エリンボルク オスターマン
エリック パッツェルト
マルリース シュプロール
カルル−ハインツ ハイダー
ジョン ジェイ ミグリエッタ
ドンゲン アウグスティヌス アントニウス マリア シルヴェステル ファン
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング, ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2005504517A publication Critical patent/JP2005504517A/ja
Publication of JP2005504517A5 publication Critical patent/JP2005504517A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2002592353A 2001-05-18 2002-05-17 ＣＤ４４ｖ６特異的抗体 Pending JP2005504517A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01112237 2001-05-18
US32514701P 2001-09-26 2001-09-26
PCT/EP2002/005467 WO2002094879A1 (en) 2001-05-18 2002-05-17 Antibodies specific for cd44v6

Publications (2)

Publication Number Publication Date
JP2005504517A true JP2005504517A (ja) 2005-02-17
JP2005504517A5 JP2005504517A5 (https=) 2006-01-05

Family

ID=33442672

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002592353A Pending JP2005504517A (ja) 2001-05-18 2002-05-17 ＣＤ４４ｖ６特異的抗体

Country Status (18)

Country Link
EP (1) EP1397387A1 (https=)
JP (1) JP2005504517A (https=)
CN (1) CN1541226A (https=)
AR (1) AR036154A1 (https=)
BR (1) BR0210905A (https=)
CA (1) CA2443437A1 (https=)
CZ (1) CZ20033476A3 (https=)
EA (1) EA200301169A1 (https=)
EC (1) ECSP034838A (https=)
EE (1) EE200300569A (https=)
HU (1) HUP0400030A3 (https=)
MX (1) MXPA03010523A (https=)
PE (1) PE20021098A1 (https=)
PL (1) PL365735A1 (https=)
SK (1) SK15592003A3 (https=)
WO (1) WO2002094879A1 (https=)
YU (1) YU91403A (https=)
ZA (1) ZA200307365B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023516080A (ja) * 2020-03-06 2023-04-17 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｄ４４抗体およびその使用
JP2024512324A (ja) * 2021-03-05 2024-03-19 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｄ４４抗体およびその使用

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100542A1 (en) 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
CA2556027C (en) 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
CA2600505C (en) 2005-03-10 2016-05-03 Morphotek, Inc. Anti-mesothelin antibodies
EP2172487A1 (en) 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
SG182191A1 (en) * 2007-06-13 2012-07-30 Zymogenetics Inc Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus
EP2009028A1 (en) * 2007-06-27 2008-12-31 Monoclonal Antibodies Therapeutics Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors
SI2531527T1 (sl) 2010-02-04 2014-07-31 F. Hoffmann-La Roche Ag Monoklonsko protitelo proti CD44 za uporabo pri zdravljenju skvamoznoceličnega karcinoma glave in vratu
CN102337298B (zh) * 2011-08-19 2013-11-06 黄开红 一种输送siRNA的免疫纳米载体及其制备方法和应用
WO2013083497A1 (en) 2011-12-06 2013-06-13 F. Hoffmann-La Roche Ag Antibody formulation
WO2017215637A1 (zh) * 2016-06-15 2017-12-21 李翀 一种人子宫内膜癌的标志物、抗体及其应用
CN107556388A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0438310A1 (en) * 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
JPH08506801A (ja) * 1992-11-20 1996-07-23 アイシス・イノベーション・リミテッド Ｃｄ４４エキソン６に対応するペプチド、そのペプチドに特異的な抗体、および、腫瘍診断にそれらの抗体を使用する方法
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти
UY24389A1 (es) * 1995-12-06 2001-10-25 Karlsruhe Forschzent Composición farmacéutica para el tratamiento de carcinoma de epitelio plano

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023516080A (ja) * 2020-03-06 2023-04-17 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｄ４４抗体およびその使用
JP2024512324A (ja) * 2021-03-05 2024-03-19 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｄ４４抗体およびその使用

Also Published As

Publication number Publication date
CN1541226A (zh) 2004-10-27
WO2002094879A1 (en) 2002-11-28
CZ20033476A3 (cs) 2004-05-12
PL365735A1 (en) 2005-01-10
PE20021098A1 (es) 2003-02-11
EA200301169A1 (ru) 2004-06-24
HUP0400030A3 (en) 2006-02-28
ECSP034838A (es) 2003-12-24
YU91403A (sh) 2006-05-25
EE200300569A (et) 2004-04-15
CA2443437A1 (en) 2002-11-28
BR0210905A (pt) 2004-06-08
HUP0400030A2 (hu) 2004-04-28
MXPA03010523A (es) 2004-07-01
ZA200307365B (en) 2004-05-10
AR036154A1 (es) 2004-08-18
EP1397387A1 (en) 2004-03-17
SK15592003A3 (sk) 2004-06-08

Similar Documents

Publication Publication Date Title
US6972324B2 (en) Antibodies specific for CD44v6
Börjesson et al. Phase I therapy study with 186Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma
Divgi et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma.
JP5646652B2 (ja) 放射免疫コンジュゲートおよびその使用
JP2005504517A (ja) ＣＤ４４ｖ６特異的抗体
TWI294969B (https=)
JP2020022470A (ja) ヒト化抗カリクレイン−２抗体
US20110091460A1 (en) Receptor-targeting reagents
JP6037149B2 (ja) 頭頸部扁平上皮癌の治療に使用されるｃｄ４４に対するモノクローナル抗体
JP2004532639A (ja) 前立腺特異的膜抗原に対する修飾抗体およびその使用
JP2005527488A (ja) Ｍｅｔを発現し、肝細胞増殖因子と結合する腫瘍のモノクローナル抗体画像化および治療
US20240368269A1 (en) Anti-dll3 antibodies and uses thereof
JP2008535865A (ja) 抗ｐｓｍａコンジュゲート抗体
Kalofonos et al. Antibody‐guided diagnosis and therapy of malignant lesions
US20220296737A1 (en) Immunopet and immunospect imaging to identify cytotoxic t cell activity
KR20040000478A (ko) ＣＤ44ｖ6에 특이적인 항체
AU2002310823A1 (en) Antibodies specific for CD44v6
Krause et al. Human monoclonal antibody99mTc-88BV59: Detection of colorectal cancer, recurrent or metastatic disease and immunogenicity assessment
JP2020505462A (ja) 骨髄関連疾患の治療に使用するための放射性免疫複合体
WO2025207781A1 (en) Antibody radioisotope constructs
TW202606757A (zh) 用於治療前列腺癌之組成物及方法
AU4901300A (en) Method of treating carcinoma using antibody therapy and ameliorating side effects associated with such therapy
WO2000074719A1 (en) Method of treating carcinoma using antibody therapy and ameliorating side effects associated with such therapy
HK1175186A (en) A monoclonal antibody to cd44 for use in the treatment of head and neck squamous cell carcinoma
BR122020023278B1 (pt) Uso de um polipeptídeo anticorpo para a fabricação de um medicamento para o tratamento e/ou diagnóstico de câncer de próstata

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080609

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081110